Cytos Slashes Programs, Jobs To Keep Allergy Candidate Alive
By Catherine Shaffer
Thursday, August 18, 2011
Cytos Biotechnology Ltd. is taking drastic measures to keep the company afloat ahead of the looming maturity of its convertible bond in February 2012. Although its product, CYT003-QbG10, has shown positive results in three Phase II trials for allergic asthma and allergic rhinitis, the company has been unable to fund its earlier stage programs, and may face a financing gap of more than $21.5 million even after it slashes its staff and programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.